| Yang, Yang |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
| Terminated | 3 | 372 | Europe, US, RoW | Pamrevlumab, FG-3019, Placebo | FibroGen | Idiopathic Pulmonary Fibrosis | 09/23 | 09/23 | | |
|
NCT05043688: Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. |
|
|
| Recruiting | 3 | 426 | RoW | Camrelizumab, radiotherapy | Zhigang Li, Jiangsu HengRui Medicine Co., Ltd. | Resectable Esophageal Squamous Cell Carcinoma | 12/28 | 12/30 | | |
NCT05417321: A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 80 | US, RoW | HB0036, Anti-PD-L1 and anti-TIGIT bifunctional molecule | Shanghai Huaota Biopharmaceutical Co., Ltd. | Advanced Solid Tumor, NSCLC | 08/25 | 08/25 | | |
| Lai, Wei |
YM-1, NCT06441799: Study on the Safety, Efficacy of Home RF Cosmetic Instrument in the Treatment of Facial or Periorbital Wrinkles |
|
|
| Completed | N/A | 224 | RoW | Home radiofrequency skin treatment instrument, Ultrasonic coupler for medical purposes | Glomed(HN)Co.Ltd | Skin Wrinkles | 08/23 | 08/23 | | |
| Li, Hua |
| Not yet recruiting | 3 | 420 | RoW | Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Endometrial Cancer | 12/27 | 06/29 | | |
NCT06470191: A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. |
|
|
| Recruiting | 2/3 | 216 | RoW | B007, Cyclosporin Capsules | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Primary Membranous Nephropathy | 12/26 | 12/26 | | |
NCT04492787: Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) |
|
|
| Completed | 2 | 240 | NA | Changkang Granule, Changkang Placebo Granule | Tasly Pharmaceutical Group Co., Ltd | Irritable Bowel Syndrome with Diarrhea | 04/22 | 04/22 | | |
NCT04839926: A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese Subjects |
|
|
| Recruiting | 1 | 60 | RoW | 0.5mg CY150112, placebo, 1.5mg CY150112, 4.5mg CY150112, 10mg CY150112, 18mg CY150112, 24mg CY150112 | Jiangsu Nhwa Pharmaceutical Co., Ltd. | Schizophrenia | 08/21 | 08/21 | | |
TQB2618-AK105-Ib-04, NCT05975645: A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). |
|
|
| Recruiting | 1 | 40 | RoW | Penpulimab injection, TQB2618 injection, Anlotinib Hydrochloride Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma | 12/24 | 04/25 | | |
| Completed | N/A | 52 | US | Halcyon 4.0 system | Washington University School of Medicine, Varian Medical Systems | Brain Cancer, Head and Neck Cancer, Lung Cancer, Gastric Cancer, Ovarian Cancer, Colon Cancer | 10/24 | 10/24 | | |
SCDB, NCT06422845: Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula Stenosis |
|
|
| Recruiting | N/A | 328 | RoW | Dissolve AV Peripheral Scoring Drug-coated Balloon, Scoring Drug-coated Balloon | DK Medical Technology (Suzhou) Co., Ltd. | Arteriovenous Fistula Stenosis | 07/27 | 07/27 | | |
| Zhang, Qi |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT05224960: Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2) |
|
|
| Recruiting | 2 | 140 | RoW | UC-MSCs, Placebo(solution without UC-MSCs) | Beijing 302 Hospital, Chinese PLA General Hospital, Shanghai Changzheng Hospital, LanZhou University, Jin Yin-tan Hospital, Hainan Hospital of Chinese PLA General Hospital, Vcanbio Cell and Gene Engineering Corp., Ltd., Third Affiliated Hospital, Sun Yat-Sen University, Xinjiang Kashi Area Number 1 Hospital | Decompensated Cirrhosis | 06/25 | 06/27 | | |
NCT06461624: Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 15 | RoW | anti-GPC3 CAR-T, CBG166 CAR-T | Zhejiang University, Carbiogene Therapeutics Co. Ltd. | Advanced Hepatocellular Carcinoma | 07/27 | 10/27 | | |
| Not yet recruiting | N/A | 220 | RoW | Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR), Paclitaxel-Eluting Balloon (Bingo) | CCRF Inc., Beijing, China | Percutaneous Coronary Intervention | 05/22 | 10/22 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Zhao, Hui |
ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 738 | RoW | TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Extensive Small Cell Lung Cancer | 12/22 | 12/22 | | |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
NCT05629390: Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study |
|
|
| Completed | 3 | 163 | RoW | Lotilaner, TP-03, S-Misoxam, Vehicle Control | LianBio LLC | Blepharitis | 09/23 | 04/24 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
| Recruiting | 2 | 54 | RoW | KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection), Axitinib | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Non-small Cell Lung Cancer | 05/27 | 12/27 | | |
NCT04973735: A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects |
|
|
| Active, not recruiting | 1 | 42 | RoW | LY-CovMab | Luye Pharma Group Ltd., Shandong Boan Biotechnology Co Ltd | Covid19 | 05/21 | 07/21 | | |
NCT03814447: The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer |
|
|
| Recruiting | 1 | 10 | RoW | anti- MESO CAR-T cells, Fludarabine, FA, Cyclophosphamide, CTX | Shanghai 6th People's Hospital, Hrain Biotechnology Co., Ltd. | Ovarian Cancer | 01/23 | 01/23 | | |
NCT02929290: Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC |
|
|
| Recruiting | 1 | 80 | RoW | BPI-9016M, No other name so far | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 11/24 | 11/24 | | |
NCT05895565: A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects |
|
|
| Recruiting | 1 | 28 | RoW | PMG1015, PMG1015 placebo | Pulmongene Ltd. | IPF | 12/24 | 05/25 | | |
NCT04948502: SaExten Vena Cava Filter System in Prevention of Pulmonary Embolism |
|
|
| Completed | N/A | 192 | RoW | SaExten vena cava filter system, SaExten VCF system, Denali inferior vena cava filter, Denali IVCF | ShenZhen KYD Biomedical Technology Co., Ltd. | Pulmonary Embolism | 01/22 | 09/22 | | |
| Liu, Bo |
| Completed | 3 | 1412 | RoW | Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA | Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 06/23 | | |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
NCT05371080 / 2021-005319-30: A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults |
|
|
| Active, not recruiting | 3 | 3038 | Europe, Canada, Japan, US, RoW | HZ/su vaccine | GlaxoSmithKline | Herpes Zoster | 08/27 | 08/27 | | |
NCT05254665: A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 2 | 110 | RoW | Docetaxel Polymeric Micelles for Injection | Jiangsu Simcere Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/22 | 03/24 | | |
NCT05068206: A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx |
|
|
| Recruiting | 2 | 120 | RoW | AK105 injection, Anlotinib hydrochloride capsule, CapeOX, Bevacizumab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unresectable Metastatic Colorectal Cancer | 12/23 | 06/24 | | |
NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC |
|
|
| Recruiting | 2 | 60 | RoW | HLX07+HLX10+ Cisplatin+5-FU, HLX07 | Shanghai Henlius Biotech | ESCC or Esophageal Adenosquamous Carcinoma | 06/24 | 08/25 | | |
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Benmelstobart/Penpulimab With or Without Capecitabine in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 168 | RoW | TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Capecitabine | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Gastroesophageal Adenocarcinoma | 09/26 | 09/27 | | |
NCT05686642: Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke |
|
|
| Recruiting | 2 | 300 | RoW | LT3001 Drug:high dose, Placebo, LT3001 Drug:low dose | Shanghai Pharmaceuticals Holding Co., Ltd | Acute Ischemic Stroke | 04/25 | 07/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
| Recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
|
| Completed | N/A | 60 | RoW | Avocado extract, Placebo | University of Adelaide, Isagenix International LLC, Commonwealth Scientific and Industrial Research Organisation, Australia, Prolongevity Technologies | Obesity | 08/22 | 08/22 | | |
| Recruiting | N/A | 701 | RoW | Liver-cancer early detection test | The First Hospital of Jilin University, Guangzhou Burning Rock Dx Co., Ltd. | Liver Cancer | 12/23 | 12/23 | | |
| Guoying, Wang |
| No trials found |
| Yi, Huimin |
| No trials found |
| Lv, Haijin |
| No trials found |
| chen, huiqin |
| No trials found |
| Li, Siqi |
| No trials found |
| Zhang, Yingcai |
| No trials found |
| Mo, Jian |
| No trials found |
| Yu, Haoyuan |
| No trials found |
